PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Genomic Tumor Profiling for Neoantigens in Colorectal Cancer Immunotherapy

Abstract 7277: Comprehensivegenomic tumor profiling identifies functional neoantigens to predict adjuvant chemotherapy benefit and optimize personalized immunotherapy in colorectal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

LTLe Son TranBNBui Que Tran Nguyen

Discussion

Loading...

Member takes

Overview

Comprehensive genomic analysis predicts chemotherapy benefit in stage III colorectal cancer, suggesting enhanced personalized treatment strategies.

Key Points

  • This study aims to identify functional neoantigens to improve chemotherapy efficacy and personalize immunotherapy in colorectal cancer patients.
  • Analyzed neoantigen landscapes in 66 stage II/III colorectal cancer patients.
  • Utilized DNA, RNA, and TCR sequencing for comprehensive genomic profiling.
  • Employed NetMHCpan, PRIME, and DeepImmuno to predict neoantigens from various genomic sources.
  • Conducted ELISpot assays to assess ex vivo immunogenicity of neoantigens.
  • Characterized neoantigen-specific T cells using single-cell RNA/TCR sequencing.
  • Gene fusion-derived neoantigens showed broader HLA-binding affinities compared to SNV/indel-derived neoantigens.
  • GFn burden inversely correlated with SNV/indel burden, indicating GFNs as a distinct neoantigen source.
  • FTICS correlated strongly with progression-free survival (PFS) with an AUC of 0.70.
  • 57.1% of patients exhibited T cell responses to GFNs, similar to SNV/indel responses.
  • CD8+ T cells demonstrated stronger activity against GFNs compared to SNV-derived counterparts.

Cite This Study

Tran et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd4ea79560c99a0a33cchttps://doi.org/10.1158/1538-7445.am2026-7277
View Full Paper
Ask AI
Bookmark
Share